CollPlant Biotechnologies (CLGN) Total Debt (2017 - 2020)

CollPlant Biotechnologies' (CLGN) quarterly Total Debt came in at $12000.0 in Q2 2020, down 50.0% on a QoQ basis from $24000.0 in Q4 2019.

CollPlant Biotechnologies (CLGN) Total Debt (2017 - 2020) Analysis & Trends

CollPlant Biotechnologies (CLGN) has 4 years of Total Debt data on file, last reported at $12000.0 in Q2 2020.

Quarterly Total Debt changed N/A year-over-year to $12000.0 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $12000.0 (changed N/A YoY) and the FY2019 annual result came in at $24000.0, changed N/A from the prior year.
Total Debt retreated to $12000.0 in Q2 2020, from $24000.0 in the prior quarter.
In the past five years, Total Debt ranged from a high of $3.6 million in Q4 2017 to a low of $12000.0 in Q2 2020.
A 4-year average of $934750.0 and a median of $41000.0 in 2018 frame the typical range for Total Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.34 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	770.36 Mn
10	CollPlant Biotechnologies	4.13 Mn	4.13 Mn	-243,000.00	-

Download Data